Biopharma

Opinion: Why we study shrimp on treadmills: The case fo...

“If we cut or limit funding for curiosity-driven research, we risk shutting down...

Opinion: The Johnson & Johnson cancer drug scandal that...

Erythropoietin, aka EPO, is best known for its role in the Lance Armstrong cheat...

STAT+: What FDA cuts could mean for the future of tobacco

FDA and CDC cuts will only exacerbate problems with tobacco regulation and enfor...

Why a small journal’s ‘blueprint for NIH’ is getting so...

A paper proposing NIH reforms is circulating in academic circles and within the ...

Clinical Trials Information System designated as WHO pr...

The Clinical Trials Information System (CTIS) has been designated as a primary r...

Cyclacel Pharmaceuticals sheds clinical cancer asset in...

Struggling Cyclacel Pharmaceuticals is dropping one of its two clinical stage as...

Lawmakers Want School Meal Programs to Allow Whole Milk...

WEDNESDAY, April 2, 2025 -- Whole and 2 percent milk may be coming back to scho...

As Trump's 'Liberation Day' tariffs seem to spare pharm...

On Wednesday, President Donald Trump unveiled another wave of tariffs but did no...

Scientists sue NIH, saying politics cut their research ...

The suit filed Wednesday aims to restore funding and end grant cancellations, ar...

Opinion: Decimation of HHS comms, FOIA offices will lea...

“Health Secretary Robert F. Kennedy Jr. took office promising ‘radical transpare...

Trump installs sweeping new tariffs, but pharma appears...

The president will impose a baseline 10% tariff on all countries, as well as hig...

New York City’s health department just lost $100 millio...

With $100 million in federal funds suddenly revoked, New York City’s acting heal...

STAT+: Makary’s first speech to FDA staff focuses on ch...

Makary said little about specific plans for his agency or about the layoffs that...

Concentra swoops in to buy struggling Allakos, softenin...

Tang Capital Partners-owned Concentra inked an Allakos acquisition agreement aft...

A letter from the executive editor: The dramatic reshap...

The Trump administration and health secretary Robert F. Kennedy Jr. are ushering...

Brookfield to buy laboratory equipment group Antylia Sc...

Deal is latest sign of the uptick in exits by private equity groups despite slug...

Elon Musk expected to step down from DOGE leadership ro...

In the upcoming weeks, Tesla CEO Elon Musk is expected to step down from his pos...

Elon Musk to step down from DOGE leadership role: Politico

In the upcoming weeks, Tesla CEO Elon Musk is expected to step down from his pos...

With biosimilar competition looming, Roche takes a hit ...

With its multiple sclerosis powerhouse Ocrevus expected to lose patent protectio...

'Patently illegal': NIH and HHS face new lawsuit over $...

The American Public Health Association and several researchers are suing the NIH...

For struggling cell and gene therapy field, Peter Marks...

To innovators in the cell and gene therapy field, Peter Marks’ exit from the FDA...

‘Patently illegal’: NIH and HHS face new lawsuit over $...

The American Public Health Association and several researchers are suing the NIH...

Cerevance fails phase 2 trial in early, untreated Parki...

Cerevance’s attempt to unlock the first-line Parkinson's disease market has hit ...

STAT+: Trump administration begins mass cuts of federal...

ASPE and AHRQ are losing key research staff as part of the HHS cuts Tuesday. Cur...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.